Planning Pregnancy, Pregnant, or Breastfeeding on Ozempic, Wegovy or Mounjaro

If you use Ozempic, Wegovy or Mounjaro and pregnancy becomes relevant, the answer depends on the exact medicine, why you take it, and which of three situations you are in:

1. you are planning pregnancy
2. you might be pregnant or have a positive pregnancy test
3. you are breastfeeding

Those are not the same question. Current European Medicines Agency product information is also not identical for semaglutide and tirzepatide.

Current EU product information also says women of childbearing potential are recommended to use contraception while treated with semaglutide or tirzepatide.

Why the brand matters in Europe

These medicines are not interchangeable in EU product information.

• Ozempic is indicated in the EU for adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
• Wegovy is indicated in the EU for weight management, including weight loss and weight maintenance, in adults with an initial BMI of at least 30, or at least 27 with at least one weight-related comorbidity, and in adolescents aged 12 years and above with obesity and body weight above 60 kg under product criteria.
• Mounjaro is indicated in the EU for adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus, and for adult weight management, including weight loss and weight maintenance, with an initial BMI of at least 30, or at least 27 to below 30 with at least one weight-related comorbid condition.

That matters because pregnancy planning for weight management is different from pregnancy planning for diabetes treatment. A person using Ozempic or Mounjaro for type 2 diabetes may need a replacement plan for glucose control before stopping the medicine.

1. If you are planning pregnancy

This is the best time to review the plan calmly rather than in a rush.

Current EU product information says:

• semaglutide products, meaning Ozempic and Wegovy, should be discontinued at least two months before a planned pregnancy
• tirzepatide, meaning Mounjaro, should be discontinued at least one month before a planned pregnancy
• women of childbearing potential are recommended to use contraception while treated with semaglutide or tirzepatide

Do not invent your own washout period. Use the current product information for the exact medicine you take.

If you use the medicine for weight management, planned pregnancy is usually the time to discuss how to protect weight maintenance, nutrition, and symptom stability once treatment stops. If you use Ozempic or Mounjaro for type 2 diabetes, the review must also cover what replaces it for glucose control.

A useful pre-pregnancy review should cover:

1. your exact brand and dose
2. why you take it, including weight management, type 2 diabetes, or both
3. when you plan to start trying
4. whether you use contraception now
5. whether nausea, vomiting, or low intake are already an issue
6. what your replacement plan is if you have diabetes
7. how you will support meals, protein intake, hydration, and weight maintenance after stopping

2. If you might be pregnant or have a positive pregnancy test

This is where patients often panic unnecessarily.

The first step is not self-blame. The first step is to confirm the situation and get prompt advice.

Current EU product information says semaglutide should not be used during pregnancy and tirzepatide is not recommended during pregnancy. It also says semaglutide or tirzepatide should be discontinued if pregnancy occurs.

What to do next:

• If pregnancy is possible, take a pregnancy test promptly.
• If the test is positive, contact the clinician managing the medicine promptly for a treatment review.
• If you use Ozempic or Mounjaro for type 2 diabetes, contact your diabetes-care team the same day or as urgently as possible for replacement glucose-management advice. Current EU product information still says the medicine should be discontinued if pregnancy occurs.
• If you were using the medicine for weight management, the review should shift from weight loss to pregnancy-safe nutrition, symptom control, and follow-up.

A positive test alone is usually not an emergency. It is a prompt medication-review issue.

What the human pregnancy data actually show

Human data are still limited, but there is some reassurance after inadvertent early exposure.

The largest human study cited here is Cesta and colleagues in JAMA Internal Medicine in 2024. This observational population-based cohort included 51,826 infants born to women with type 2 diabetes. Among them, 938 had periconceptional exposure to a GLP-1 receptor agonist. The standardised prevalence of major congenital malformations was 8.3% in the GLP-1 receptor agonist group and 7.8% in the insulin group. The adjusted relative risk was 0.95, with a 95% confidence interval of 0.72 to 1.26.

A second useful study is the 2024 BMJ Open multicentre prospective cohort by Dao and colleagues, based on six Teratology Information Services. It included 168 first-trimester GLP-1 receptor agonist exposed pregnancies, compared with 156 pregnancies in women with diabetes and 163 pregnancies in overweight or obese women. Major birth defects occurred in 2.6% of the exposed group, versus 2.3% and 3.9% in the two reference groups.

These findings are reassuring after inadvertent exposure. They are not proof that Ozempic, Wegovy, or Mounjaro should be continued during pregnancy. The studies are still limited, mostly class-level rather than medicine-specific, and not strong enough to override current EU product information.

3. If you are breastfeeding

This is where current EU wording differs most clearly by medicine.

Ozempic and Wegovy

Current EU product information says semaglutide should not be used during breast-feeding.

That means Ozempic and Wegovy are not the right choice while breastfeeding under current EU product information.

Mounjaro

Current EU product information for Mounjaro is different. It says that after a single 5 mg dose, tirzepatide in breast milk was undetectable to very low compared with plasma concentrations, and that any low amount present is expected to be degraded and not orally absorbed intact by the breastfed infant. It also says it is not known whether reduced maternal food intake caused by tirzepatide affects breast-milk composition or nutrient content. Overall, current EU product information says tirzepatide could be considered for use during breast-feeding.

That wording is not the same as a general green light. A breastfeeding decision still needs individual review of:

• whether the medicine is being used for diabetes or weight management
• whether maternal intake is adequate
• whether nausea, vomiting, or low appetite are limiting recovery or milk supply
• what the mother wants to prioritise right now
• whether postponing restart would be safer or more practical

Routine versus urgent actions

Arrange prompt review

Arrange prompt clinician or pharmacist review if:

• you are planning pregnancy
• you might be pregnant or have a positive pregnancy test
• you are breastfeeding and want medicine-specific advice
• you use Ozempic or Mounjaro for type 2 diabetes and pregnancy planning means treatment has to change
• you have repeated vomiting, low intake, or dehydration risk while pregnancy or breastfeeding questions are active

Seek urgent medical help

Seek urgent medical help if you have:

• severe persistent abdominal pain
• persistent vomiting and cannot keep fluids down
• signs of dehydration such as very low urine output, feeling faint, or worsening weakness
• chest pain, shortness of breath, or other chest symptoms
• a severe allergic reaction

Pregnancy status does not make those symptoms safe to watch at home.

Why this is also a maintenance question

For Élan Clinic, this is not only a medication warning topic. It is a maintenance topic.

Pregnancy planning, an unplanned pregnancy, and the postpartum period are all moments when a weight-management plan can become unstable. Appetite, intake, nausea, exercise tolerance, glucose control, and body weight may all change quickly. If the plan is only to stay on the medicine until circumstances force a change, the patient is left exposed at exactly the point where support matters most.

A maintenance-focused review should therefore ask two questions at the same time:

1. what does the current EU product information say for this exact medicine
2. what is the safest plan for nutrition, glucose control, and weight stability once treatment changes

Frequently asked questions

The bottom line

If pregnancy becomes relevant while you are on Ozempic, Wegovy or Mounjaro, check the exact medicine first and use current EU product information, not generic internet advice.

For planned pregnancy, current EU product information says stop Ozempic or Wegovy at least two months before pregnancy and stop Mounjaro at least one month before pregnancy. Women of childbearing potential are recommended to use contraception while treated with semaglutide or tirzepatide. If pregnancy occurs, current EU product information says the medicine should be discontinued. If you use Ozempic or Mounjaro for type 2 diabetes, arrange urgent replacement glucose-management advice the same day or as promptly as possible. During breast-feeding, current EU wording differs: Ozempic and Wegovy should not be used, while Mounjaro needs an individual review rather than a generic yes or no.

This article provides general education and does not replace individual medical, diabetes, obstetric, or pharmacy advice.